Michael H. Arenberg joined Angitia in April 2024 as Chief Financial Officer with responsibility for all financial and capital market activities, including investor relations, accounting, financial reporting, strategic communications, strategic planning, financial planning and analysis, and additional operational responsibilities.
Prior to joining Angita, Mr. Arenberg was Chief Operating Officer and Chief Business Officer at Imago BioSciences where he was responsible for overseeing all capital market activities, including investor relations, corporate and business development, information technology, commercial planning, and additional operational responsibilities. He led the deal process that led to the $1.35 billion acquisition of Imago by Merck in 2023
Prior to joining Imago, Mr. Arenberg was Chief Financial Officer (CFO) at Durect Corporation, a clinical stage biopharmaceutical company, where he was responsible for overseeing all financial and capital market activities, including accounting, financial reporting, financial planning and analysis, and investor relations, with additional operational responsibilities, including business and corporate development, IT, HR and strategic planning and served as Corporate Secretary. Prior to becoming CFO, Mr. Arenberg served as Senior Vice President, Corporate and Business Development, where he negotiated and closed over 70 strategic transactions. Prior to joining Durect, Mr. Arenberg was a co-founder of IntraEAR, Inc. a medical device start-up company that was acquired by Durect.
Mr. Arenberg earned his law degree from the University of Denver Sturm College of Law, and his M.B.A. from the Leavy School of Business at Santa Clara University.